Nordstar Medical
Developer of a peripheral nerve block catheter intended to provide non-opioid postoperative pain treatment. The organization combines clinical and engineering expertise in regional anesthesia, device development, manufacturing, and clinical research. The company reports extensive publication activity in regional anesthesia and an expected market launch in 2027, subject to regulatory approvals.
Industries
Nr. of Employees
small (1-50)
Products
Peripheral nerve block catheter device (non-opioid postoperative pain treatment)
A catheter system designed for peripheral nerve blocks intended to provide postoperative analgesia without opioids, with stated goals of faster placement, reduced dislocation rates, and improved placement accuracy.
Peripheral nerve block catheter device (non-opioid postoperative pain treatment)
A catheter system designed for peripheral nerve blocks intended to provide postoperative analgesia without opioids, with stated goals of faster placement, reduced dislocation rates, and improved placement accuracy.
Expertise Areas
- Regional anesthesia and peripheral nerve block techniques
- Medical device design and prototyping
- Clinical research and evidence generation
- MedTech manufacturing and scale-up
Key Technologies
- Peripheral nerve block catheter systems
- Ultrasound-guided nerve block techniques
- Catheter anchoring / migration-resistant design
- Injection molding for medical devices
News & Updates
Company reports 50+ medical publications in regional anesthesia.
Company states 15 years backed by clinical research supporting its work.
Company reports 100+ combined years of experience across R&D, manufacturing, and innovation within the team.
The website lists an expected market launch year of 2027, conditional on regulatory approval.
Company reports 50+ medical publications in regional anesthesia.
Company states 15 years backed by clinical research supporting its work.
Company reports 100+ combined years of experience across R&D, manufacturing, and innovation within the team.
The website lists an expected market launch year of 2027, conditional on regulatory approval.